PPBT

Purple Biotech

PPBT, USA

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.

https://purple-biotech.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PPBT
stock
PPBT

Purple Biotech Ltd. (PPBT) Stock Price | Live Quotes & Charts | NASDAQ StocksToTrade

Read more →
PPBT
stock
PPBT

Purple Biotech Announces Positive Preclinical Data at ESMO IO Congress 2025 TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$34

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-3.99 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-3.35 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.19

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 1.91% of the total shares of Purple Biotech

1.

UBS Group AG

(0.7637%)

since

2025/06/30

2.

Kingswood Wealth Advisors LLC

(0.5543%)

since

2025/06/30

3.

BNP Paribas Arbitrage, SA

(0.2071%)

since

2025/06/30

4.

Morgan Stanley - Brokerage Accounts

(0.1507%)

since

2025/06/30

5.

GAMMA Investing LLC

(0.1462%)

since

2025/06/30

6.

Fidelity Nasdaq Composite Index

(0.0404%)

since

2024/10/31

7.

Rhumbline Advisers

(0.0356%)

since

2025/06/30

8.

Royal Bank of Canada

(0.0035%)

since

2025/06/30

9.

Northwestern Mutual Wealth Management Co

(0.0028%)

since

2025/06/30

10.

SIMPLEX TRADING, LLC

(0.0017%)

since

2025/06/30

11.

SBI Securities Co Ltd

(0.0007%)

since

2025/06/30

12.

Global Retirement Partners, LLC.

(0.0005%)

since

2025/06/30

13.

TD Waterhouse Canada Inc

(0%)

since

2025/03/31

14.

Tower Research Capital LLC

(0%)

since

2025/03/31

15.

Group One Trading, LP

(0%)

since

2025/03/31

16.

TWO SIGMA SECURITIES, LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.2874

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(4.5)
Net Net
Possible Net-Net(4)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.